Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4783MR)

This product GTTS-WQ4783MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4783MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7576MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ14832MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ15713MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ1326MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ3941MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ3742MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ3378MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ5716MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW